| Identification | Back Directory | [Name]
Polymyxin B | [CAS]
1404-26-8 | [Synonyms]
Polymyxin E see Colistin
polymyxin B 2.5sulfate entahydrate
Polymyxin B (base and/or unspecified salts) | [EINECS(EC#)]
215-768-4 | [Molecular Formula]
C55H96N16O13 | [MDL Number]
MFCD01775374 |
| Chemical Properties | Back Directory | [alpha ]
5461 -106.3° (1N HCl) | [form ]
Solid | [color ]
White to light yellow | [Contact allergens]
Active against Gram-negative
bacteria, Polymyxin B is a mixture of Polymyxin B1
and B2. Sensitization occurs by topical, ophthalmic,
and otic preparations. Cosensitization is frequent
with other topical antibiotics like neomycin or
bacitracin. |
| Hazard Information | Back Directory | [Definition]
ChEBI: A polymyxin having a 6-methylheptanoyl group at the amino terminus. | [Description]
Polymyxin B was isolated by Wellcome Research Laboratories, in 1949, from the mixture of polymyxins A, B, C, and D produced byBacillus polymyxa. It was later separated into the major component, B1, and the minor component, B2. Polymyxin B is a basic polypeptide and shows strong activity against gram-negative bacteria, but its activity against gram-positive bacteria, Mycobacterium, and fungi is weak. Because of its toxicity, it is used carefully by intramuscular injection for resistant Pseudomonas aeruginosa infections, e.g., sepsis. Polymyxin B is used orally to sterilize the gut in leukemic patients, intraspinally for meningitis, or topically. | [Uses]
Antibacterial Aerosporin. | [Brand name]
(GlaxoSmithKline); Poly-Rx (X Gen). |
|
|